English Session

SS2-1Can we approach personalized medicine in rheumatoid arthritis despite lack of insights from modern molecular markers?

	Josef Smolen	Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Austria

SS2-275 years of glucocorticoid treatment: too early for a final ordeal

	Hans W. Bijlsma	University Medical Center Utrecht, The Netherlands

SS2-3CAR T-cells, BiTEs and more - are we on the road to cure of autoimmune diseases?

	Gerd R. Burmester	Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany

SS2-4The importance of preventing damage accrual in systemic lupus erythematosus (SLE)

	Marta Mosca	University of Pisa, Italy

SS3-1Taming the Wolf- The Evolving Treatment Paradigm for Lupus Nephritis

	Maria Dall'era	University of California, San Francisco, USA

SS3-2The evolving understanding of lupus pathogenesis.

	J Michelle Kahlenberg	University of Michigan, Ann Arbor, Michigan, United States of America

SS4-1Bridging the Gap: Pitfalls in Gout Management

	Jose Paulo P. Lorenzo	University of the Philippines, Philippine General Hospital, Manila, Philippines & Makati Medical Center, Makati, Philippines

SS4-2Comorbidities in idiopathic inflammatory myopathies

	Ronald MLYip	Integrated Diagnostic and Medical centre, Tung Wah Group of Hospitals, Hong Kong

SS4-3Which test is Preferable for the Screening of Latent Tuberculosis in Refractory Spondyloarthritis Patients: Tuberculin Skin Test and or QuantiFERON TB Gold Test

	Md Nazrul Islam	Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

SS4-4The Winding Path Towards Building the APLAR Systemic Sclerosis Incident Cohort

	Andrea H. Low	Singapore General Hospital, Duke-National University of Singapore, Singapore

SS4-5Unveiling the pathology of axial spondyloarthritis in HLA-B27 negative patients through integrated analysis

	Haruka Tsuchiya	Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan

TSｰ1Systemic Lupus Erythematosus and Autoimmune Rheumatic Disorders

	Allan Gibofsky	Hospital for Special Surgery-Weill Cornell Medicine, USA

TSｰ2New Molecules in Development for Rheumatic Diseases

	Roy M. Fleischmann	University of Texas Southwestern Medical Center, USA

TSｰ3TREG Session：ACR 2024, EULAR 2024 conference topics

	Arthur Kavanaugh	Division of Rheumatology Allergy and Immunology, University of California, San Diego, USA

TSｰ4Spondyloarthritis

	Philip Mease	University of Washington School of Medicine, Seattle, WA, USA / Providence-Swedish Medical Center, Seattle, WA, USA

S1-1Glycobiology and maturation of AMPA during clinical suspect arthralgia to RA

	Tom W. Huizinga	Leiden University Medical Center, The Netherlands

S1-2Characteristics of clinically suspect arthralgia that progresses to inflammatory/rheumatoid arthritis

	Kei Ikeda	Department of Rheumatology, Dokkyo Medical University, Tochigi, Japan

S1-3Omics analysis of synovial tissue opens up a new era for rheumatoid arthritis

	Haruka Tsuchiya	Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

S1-4Bone erosion and microarchitecture changes in inflammatory arthritis analyzed by HR-pQCT

	Naoki Iwamoto	Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

S3-1Environment and Exposome in Rheumatoid Arthritis

	Marie-Christophe Boissier	Inserm U1125, Bobigny, France / University of Sorbonne Paris North, Bobigny, France / Assistance Publique-Hôpitaux de Paris, Avicenne's hospital, Department of Rheumatology, Bobigny, France

S3-2Pathogenesis of enthesitis and secondary synovitis

	Dennis McGonagle	The University of Leeds, UK

S3-3Recent progress and future potential in the imaging of inflammatory arthritis

	Yasushi Kondo	Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

S3-4Cutting-edge of the treatment of arthritis: Bridging the gap between RCTs and real-world clinical practice through cohort studies

	Kosuke Ebina	Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

S7-1A case of D2TPsA mimicking rheumatoid arthritis and requiring frequent treatment switching

	Masatoshi Kawataka	The First Department of Internal Medicine, University of Toyama Faculty of Medicine, Toyama, Japan

S7-2Difficult to treat Psoriatic Arthritis

	Cristina Macía-Villa	Ramón y Cajal University Hospital, Madrid, Spain

S7-3A Case of Axial Spondyloarthritis with Response to NSAIDs but Radiographic Progression: Challenges in Monitoring and Treatment Approaches

	Taiga Kuga	Department of Internal Medicine and Rheumatology, Juntendo University, Japan

S7-4Clinical Characteristics and Predictors of Difficult-to-Manage Axial Spondyloarthritis: Insights from a Single-Center Retrospective Study

	Yen-An Chang	Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Symposium 8

Profiling human disease immunology by single cell multi-omics analyses

Thursday, April 24　14:30-17:00　Room 12 (501, Fukuoka International Congress Center)

Chairs：	Yukinori Okada	Department of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
	Shyam Prabhakar	Genome Institute of Singapore, Singapore

S21-1New Frontiers in Autoinflammation: Dispatch from Bethesda

	Dan Kastner	National Human Genome Research Institute, USA

S21-2Recent advancement of inflammasomopathy

	Ryuta Nishikomori	Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan

S21-3Type 1 Interferonopathy

	Kazushi Izawa	Department of Pediatrics, Kyoto University Graduate School of Medicine, Japan

S21-4Sources and effects of excess IL-18 in Auto- and Hyperinflammatory Diseases

	Scott Canna	Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, USA

LS2Efficacy and Safety of JAK Inhibitors for the Management of Rheumatoid Arthritis:
Structural and Clinical Remission With Filgotinib

	Gerd R. Burmester	Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Germany / Department of Rheumatology and Clinical Immunology, Free University, Germany / Department of Rheumatology and Clinical Immunology, Humboldt University Berlin, Germany

LS17Modern Management of Rheumatoid Arthritis With JAK Inhibitors:
Evidence for the Clinical Utility of Filgotinib

	Gerd R. Burmester	Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Germany / Department of Rheumatology and Clinical Immunology, Free University, Germany / Department of Rheumatology and Clinical Immunology, Humboldt University Berlin, Germany

Panelists

	Mitsuhiro Akiyama	Department of Internal Medicine, Division of Rheumatology, Keio University School of Medicine
	Tadashi Okano	Center for Senile Degenerative Disorders（ CSDD）, Department of OrthopaedicSurgery, Osaka Metropolitan University Graduate School of Medicine
	Kosaku Murakami	Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University

LS27The Role of IL6 in Optimizing Treatment in Patient with Rheumatoid Arthritis

	Tom W. Huizinga	Leiden University Medical Center, Leiden, The Netherlands

Lunchen Seminar 32

ANCA associated vasculitis, AAV

Saturday, April 26　12:25-13:25　Room 2 (Palace Room, Fukuoka Sunpalace)

Chairs：	Masayoshi Harigai	Sanno Medical Center/Department of Rheumatology and Collagen Disease, International University of Health and Welfare School of Medicine
	Naoto Tamura	Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine

ES1―

	Gerd R. Burmester	Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin, Berlin, Germany.

ES9-1The major role of interleukin（ IL） -6 receptor（ R） blockade in Rheumatoid arthritis（ RA） and inflammatory conditions:

	Josef S. Smolen	Division of Rheumatology Department of Medicine 3, Medical University of Vienna, Austria

ES9-2Celebrating 20 years of Ineterleukin-6 signal blocking therapy

	Tsutomu Takeuchi	Saitama Medical University / Keio University School of Medicine

ES17Screening, evaluation, and treatment of systemic autoimmune rheumatic diseases based on recently published guidelines

	Shervin Assassi	Division of Rheumatology, Department of Medicine University of Texas Health Science Center at Houston, Houston, TX, USA